Vigilant Capital Management’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | $31.2M | Buy |
231,517
+6,307
| +3% | +$925K | 2.33% | 13 |
|
|
2023
Q1 | $35.9M | Sell |
225,210
-11,590
| -5% | -$1.77M | 2.91% | 10 |
|
|
2022
Q4 | $38.3M | Sell |
236,800
-8,474
| -3% | -$1.3M | 3.27% | 7 |
|
|
2022
Q3 | $32.9M | Buy |
245,274
+1,970
| +0.8% | +$283K | 3.09% | 7 |
|
|
2022
Q2 | $37.3M | Sell |
243,304
-7,212
| -3% | -$1.1M | 3.21% | 4 |
|
|
2022
Q1 | $40.6M | Sell |
250,516
-12,220
| -5% | -$1.78M | 3.1% | 7 |
|
|
2021
Q4 | $35.6M | Buy |
262,736
+9,246
| +4% | +$1.09M | 2.49% | 10 |
|
|
2021
Q3 | $27.3M | Buy |
253,490
+5,225
| +2% | +$597K | 2.19% | 12 |
|
|
2021
Q2 | $28M | Buy |
248,265
+3,155
| +1% | +$355K | 2.26% | 12 |
|
|
2021
Q1 | $26.5M | Buy |
245,110
+1,595
| +0.7% | +$171K | 2.36% | 13 |
|
|
2020
Q4 | $26.1M | Buy |
243,515
+12,394
| +5% | +$1.19M | 2.5% | 12 |
|
|
2020
Q3 | $20.2M | Buy |
231,121
+391
| +0.2% | +$36.8K | 2.22% | 16 |
|
|
2020
Q2 | $22.7M | Buy |
230,730
+809
| +0.4% | +$71.2K | 2.75% | 8 |
|
|
2020
Q1 | $17.5M | Sell |
229,921
-116
| -0.1% | -$9.88K | 2.56% | 10 |
|
|
2019
Q4 | $20.4M | Buy |
230,037
+5,298
| +2% | +$440K | 2.36% | 11 |
|
|
2019
Q3 | $17M | Buy |
224,739
+16,123
| +8% | +$1.11M | 2.21% | 15 |
|
|
2019
Q2 | $15.2M | Buy |
208,616
+16,295
| +8% | +$1.28M | 2.03% | 21 |
|
|
2019
Q1 | $15.5M | Sell |
192,321
-19,417
| -9% | -$1.59M | 2.16% | 13 |
|
|
2018
Q4 | $19.5M | Buy |
211,738
+2,864
| +1% | +$252K | 3.1% | 5 |
|
|
2018
Q3 | $19.8M | Buy |
208,874
+1,776
| +0.9% | +$168K | 2.63% | 7 |
|
|
2018
Q2 | $19.2M | Buy |
207,098
+931
| +0.5% | +$90.9K | 2.78% | 6 |
|
|
2018
Q1 | $19.5M | Buy |
206,167
+36,574
| +22% | +$4.02M | 2.78% | 6 |
|
|
2017
Q4 | $16.4M | Buy |
169,593
+3,823
| +2% | +$360K | 2.16% | 7 |
|
|
2017
Q3 | $14.7M | Buy |
165,770
+14,535
| +10% | +$1.11M | 2.19% | 7 |
|
|
2017
Q2 | $11M | Buy |
151,235
+5,980
| +4% | +$402K | 1.78% | 15 |
|
|
2017
Q1 | $9.46M | Buy |
145,255
+4,598
| +3% | +$289K | 1.65% | 23 |
|
|
2016
Q4 | $8.81M | Buy |
140,657
+1,982
| +1% | +$121K | 1.55% | 27 |
|
|
2016
Q3 | $8.75M | Sell |
138,675
-1,200
| -0.9% | -$77.7K | 1.55% | 23 |
|
|
2016
Q2 | $8.66M | Sell |
139,875
-3,305
| -2% | -$201K | 1.66% | 17 |
|
|
2016
Q1 | $8.18M | Buy |
143,180
+1,980
| +1% | +$110K | 1.63% | 24 |
|
|
2015
Q4 | $8.37M | Sell |
141,200
-163
| -0.1% | -$9.39K | 1.7% | 20 |
|
|
2015
Q3 | $7.69M | Sell |
141,363
-1,970
| -1% | -$128K | 1.54% | 26 |
|
|
2015
Q2 | $9.63M | Buy |
143,333
+1,695
| +1% | +$111K | 1.74% | 18 |
|
|
2015
Q1 | $8.29M | Buy |
141,638
+2,965
| +2% | +$179K | 1.56% | 23 |
|
|
2014
Q4 | $9.07M | Buy |
138,673
+282
| +0.2% | +$17.8K | 1.79% | 18 |
|
|
2014
Q3 | $7.99M | Buy |
138,391
+12,635
| +10% | +$701K | 1.73% | 20 |
|
|
2014
Q2 | $7.1M | Sell |
125,756
-791
| -0.6% | -$41.5K | 1.57% | 25 |
|
|
2014
Q1 | $6.5M | Sell |
126,547
-15
| -0% | -$758 | 1.54% | 26 |
|
|
2013
Q4 | $6.68M | Buy |
126,562
+1,725
| +1% | +$84.8K | 1.63% | 23 |
|
|
2013
Q3 | $5.58M | Buy |
124,837
+49,387
| +65% | +$2.19M | 1.58% | 30 |
|
|
2013
Q2 | $3.12M | Buy |
+75,450
| New | +$3.3M | 0.93% | 47 |
|
Other funds holding ABBV
Vigilant Capital Management's ABBV Position: Q2 2023 in Review
Vigilant Capital Management increased its AbbVie (ABBV) stake by 2.8% in Q2 2023, buying an estimated $925K and bringing the position to 231,517 shares worth $31.2M. The position accounts for 2.33% of the portfolio, ranked #13.
Vigilant Capital Management first reported a position in ABBV in Q2 2013 and has held it in 41 quarters since. The position peaked at $40.6M in Q1 2022. 3,076 funds tracked by Wall St. Rank hold ABBV as of Q2 2023.
- Vigilant Capital Management held 231,517 shares of AbbVie worth $31.2M as of Q2 2023.
- Vigilant Capital Management bought 6,307 AbbVie shares in Q2 2023, an estimated $925K.
- AbbVie made up 2.33% of Vigilant Capital Management's portfolio in Q2 2023, its #13 holding.
- Vigilant Capital Management first reported a position in AbbVie in Q2 2013 and has held it in 41 quarters since.
- Vigilant Capital Management's AbbVie position peaked at $40.6M in Q1 2022.
- 3,076 funds tracked by Wall St. Rank held AbbVie as of Q2 2023.
Based on Vigilant Capital Management's 13F filing for Q2 2023, filed 8 Aug 2023.